Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company has a research and service agreement with The University of Melbourne for the development and enhancement of the BREVAGenplus breast cancer risk assessment test, as well as a strategic alliance with Blockchain Global Limited. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone61-3-8412-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$140,000.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date8/29/2019 (Estimated)
OptionableOptionable
Genetic Technologies (NASDAQ:GENE) Frequently Asked Questions
What is Genetic Technologies' stock symbol?
Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE."
When is Genetic Technologies' next earnings date?
Has Genetic Technologies been receiving favorable news coverage?
Media stories about GENE stock have been trending negative recently, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Genetic Technologies earned a news impact score of -2.3 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Genetic Technologies.
Who are some of Genetic Technologies' key competitors?
Some companies that are related to Genetic Technologies include Cidara Therapeutics (CDTX), Organovo (ONVO), BioCardia (BCDA), Microbot Medical (MBOT), Entera Bio (ENTX), Vical (VICL), Mateon Therapeutics (MATN), TRACON Pharmaceuticals (TCON), Aevi Genomic Medicine (GNMX), CytRx (CYTR), Vaxart (VXRT), CytRx (CYTR), Enzon Pharmaceuticals (ENZN), Titan Pharmaceuticals (TTNP) and aTyr Pharma (LIFE).
What other stocks do shareholders of Genetic Technologies own?
Who are Genetic Technologies' key executives?
Genetic Technologies' management team includes the folowing people:
- Dr. Paul Alexander Kasian Ph.D., Exec. Chairman & CEO (Age 62)
- Dr. Jerzy Muchnicki, Exec. Director & Bus. Devel. Director
- Mr. Paul Keith Mathieson Viney B. Bus, FCPA, FGIA, FCI, COO, CFO & Company Sec.
How do I buy shares of Genetic Technologies?
Shares of GENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Genetic Technologies' stock price today?
One share of GENE stock can currently be purchased for approximately $1.77.
How big of a company is Genetic Technologies?
What is Genetic Technologies' official website?
How can I contact Genetic Technologies?
Genetic Technologies' mailing address is 60-66 HANOVER STREET, FITZROY C3, 3065. The biotechnology company can be reached via phone at 61-3-8412-7000 or via email at [email protected]
MarketBeat Community Rating for Genetic Technologies (NASDAQ GENE)
MarketBeat's community ratings are surveys of what our community members think about Genetic Technologies and other stocks. Vote "Outperform" if you believe GENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
